Jacob Francis Wood

Mr. Jacob Francis Wood

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Translation: The University of Toledo Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
OTOlivia R. Thomas
Olivia R. Thomas
MRMadhu Vishnu Sankar Reddy Rami Reddy
Madhu Vishnu Sankar Reddy Rami Reddy
JWJacob Francis Wood
Jacob Francis Wood
JTJacob J. Tan
Jacob J. Tan
THTressel Holton
Tressel Holton
Robert SmithRobert Smith
Robert Smith
Ventriculoperitoneal (VP) shunts are a common use for the treatment of hydrocephalus, which is a condition causing excessive cerebrospinal fluid (CSF) buildup in the brain. The shunt drains the CSF from the brain and into the abdomen, where it can be absorbed by the body. Although a widely used and successful procedure, it is unclear whether neurosurgical placement of this shunt may directly cause psychiatric abnormalities, especially regarding the dopaminergic system. In this paper, we first review relevant literature and discuss the dopamine circuitry in the brain. The literature suggests a shunt-associated clinical syndrome, which may include a reduction in facial and/or verbal expressivity, reduced willful movement, rigidity, and vertical gaze palsy. Typical presentation occurs within three months of a shunt revision. In patients with a VP shunt, these signs may be a strong indicator of mechanical or functional shunt malfunction. We then present two cases of hydrocephalus managed with a VP shunt, where both patients developed symptoms suggestive of psychosis and/or dopamine pathway pathology after shunt placement. We conclude that clinicians should have a suspicion for shunt-associated symptomology in patients with a history of recently treated hydrocephalus who present with psychomotor, personality, or cognitive changes.

31 March 2026 in The American Journal of Surgery
Verified
Journal Article
Closed access
MRMadhu Vishnu Sankar Reddy Rami Reddy
Madhu Vishnu Sankar Reddy Rami Reddy
PPPriyanka Pulvender
Priyanka Pulvender
JWJacob Francis Wood
Jacob Francis Wood
JTJianlin Tang
Jianlin Tang

Verified
Journal Article
Open access
PDF file
JWJacob Francis Wood
Jacob Francis Wood
JVJohn Vergis
John Vergis
Ali ImamiAli Imami
Ali Imami
WRWilliam Ryan
William Ryan
JSJon Sin
Jon Sin
Robert SmithRobert Smith
Robert Smith
The enterovirus Coxsackievirus B3 causes a range of serious health problems, including aseptic meningitis, myocarditis, and pancreatitis. Currently, Coxsackievirus B3 has no targeted antiviral treatments or vaccines, leaving supportive care as the primary management option. Understanding how Coxsackievirus B3 interacts with and alters the blood–brain barrier may help identify new therapies to combat this often-devastating infection. We reanalyzed a previously published RNA sequencing dataset for Coxsackievirus B3-infected human-induced pluripotent stem-cell-derived brain endothelial cells (iBECs) to examine how Coxsackievirus B3 altered mRNA expression. By integrating GSEA, EnrichR, and iLINCs-based perturbagen analysis, we present a novel, systems-level approach to uncover potential drug repurposing candidates for CVB3 infection. We found dynamic changes in host transcriptomic response to Coxsackievirus B3 infection at 2- and 5-day infection time points. Downregulated pathways included ribosomal biogenesis and protein synthesis, while upregulated pathways included a defense response to viruses, and interferon production. Using iLINCs transcriptomic analysis, MEK, PDGFR, and VEGF inhibitors were identified as possible novel antiviral therapeutics. Our findings further elucidate Coxsackievirus B3-associated pathways in (iBECs) and highlight potential drug repurposing candidates, including pelitinib and neratinib, which may disrupt Coxsackievirus B3 pathology at the blood–brain barrier (BBB).

10 December 2025 in Translation: The University of Toledo Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
ODOliver Dunn
Oliver Dunn
RKRia Khatri
Ria Khatri
RSRiddhima Singh
Riddhima Singh
RSRay Sun
Ray Sun
EWErica Wang
Erica Wang
JWJacob Francis Wood
Jacob Francis Wood
Lung adenocarcinoma (LACA) presents with a range of debilitating symptoms, including chronic cough, hemoptysis, and shortness of breath. In this study, we reanalyzed a published transcriptomic dataset to compare male and female LACA samples with healthy lung tissue and identify potential therapeutic targets capable of reversing disease-associated gene expression signatures. Utilizing cutting-edge bioinformatics approaches, including differential expression analysis, pathway analyses and analyses of signature-reversing drug profiles, we assessed male and female signatures separately. Using Gene Set Enrichment Analysis, we identified sex-specific differences in tumor-associated pathways, including the downregulation of blood angiogenesis in female lung adenocarcinoma subjects. Leading-edge gene analysis further revealed that angiogenesis-related genes were downregulated in both sexes, though the specific genes contributing to these pathways differed between males and females. Integrative drug repurposing analysis using the LINCs database, based on our transcriptomic profiles, uncovered potential therapeutic candidates for male and female LACA compared with healthy controls. Notably, a VEGFR inhibitor showed the highest discordance score in males, while a CLK2 inhibitor demonstrated one of the highest discordance scores in females. Together, these findings highlight distinct molecular and pharmacologic signatures between sexes and suggest potential sex-specific therapeutic strategies for lung adenocarcinoma.

5 November 2026 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Open access
PDF file
JWJacob Francis Wood
Jacob Francis Wood
MRMadhu Vishnu Sankar Reddy Rami Reddy
Madhu Vishnu Sankar Reddy Rami Reddy
SMShawn Murphy
Shawn Murphy
TDTarak Davuluri
Tarak Davuluri
AHAlastair Hoyt
Alastair Hoyt
Introduction: Chronic back pain is a leading cause of disability worldwide, contributing to reduced productivity and diminished quality of life for many patients. Spine surgery, particularly lumbar decompression and fusion, serves as an intensive intervention after conservative measures fail. Despite advances in surgical technique and instrumentation, outcomes remain highly variable, with up to half of patients experiencing little or no meaningful improvement. This variability has prompted growing interest in predictive models that forecast which patients are most likely to benefit from surgery. Methods: This review examines the current landscape of predictive modeling for patient-reported outcomes (PROs) in spine surgery. We evaluated the use of PRO instruments, which have become central to assessing surgical success. We further explored existing predictive models that incorporate demographic, clinical, and psychosocial variables, as well as emerging applications of artificial intelligence (AI) and machine-learning techniques aimed at improving diagnostic accuracy and prognostic performance. Results: Current predictive models demonstrate variable performance across populations and remain constrained by incomplete datasets, inconsistencies in definitions, and limited integration of psychosocial factors. While most models report moderate discrimination for categorical outcomes (AUC 0.62–0.84), the subjective nature of PROs and the complexity of postoperative recovery pose challenges to accurate prediction. Machine-learning approaches, including neural networks, show promise in identifying complex relationships among diverse predictors of surgical outcomes. Future advancements will rely on leveraging multimodal data sources and integrating them through AI-driven frameworks. Transparency and external validation remain essential for clinical implementation. Conclusion: While PROs remain essential for understanding patient experiences and benchmarking surgical success, they often fall short as standalone predictive tools. The next generation of modeling should integrate multidimensional data and utilize AI’s capacity to detect clinically meaningful patterns. When implemented, these models have the potential to enhance preoperative counseling, guide surgical decision-making, and advance personalized spine care.

2 June 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
JWJacob Francis Wood
Jacob Francis Wood
JTJacob J. Tan
Jacob J. Tan
HEHunter M. Eby
Hunter M. Eby
WRWilliam M. Rees
William M. Rees
JVJohn M. Vergis
John M. Vergis
Robert SmithRobert Smith
Robert Smith
Real‐world clinical databases offer students, residents, fellows, clinician‐educators, librarians, and early‐career investigators an accessible entry point into population health, quality improvement, and outcomes research. Leveraging large‐scale, de‐identified datasets enables the investigation of healthcare delivery, cost, treatment effectiveness, and clinical outcomes without the need for patient recruitment or extensive funding sources. This review provides a synopsis of four widely used real‐world clinical datasets: the Healthcare Cost and Utilization Project (HCUP, low‐cost with a Data Use Agreement), the Medical Information Mart for Intensive Care (MIMIC‐IV, openly available), TriNetX (subscription‐based), and Epic Cosmos (institutional access). Highlighting their structure, data types, access requirements, and ideal use cases, the distinguishing features of each database are discussed. Finally, we provide guidance on how learners and research teams can formulate research questions, identify the appropriate dataset, and leverage mentorship resources for database‐focused research, allowing them to meaningfully engage in data‐driven research and contribute to improving healthcare delivery and patient outcomes.